The improvement in ESS and AHI caused by GLP-1 RA is correlated with weight loss, BMI, and reduced waist circumference [45, 49, 82]
As with similar receptor agonists, side effects continue to be evaluated through clinical trials
CBO projects that legislation repealing the prohibition would increase drug spending by $38 billion, with offsetting health savings of $3 billion, over the 2026-2034 period
Notably, this shift closely paralleled the expanded use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight management
Likewise, production of Semaglutide generics is not expected in Europe till 2031-2032 due to extended patent protection
The hormonal imbalances that come with PCOS can further complicate this process